Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 18/20 | 0.71 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963089 | 1.00 | MAPKAPK5 (0.71) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL29696952 | 0.91 | MAPKAPK5 (0.68) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL9110420 | 0.91 | MAPKAPK5 (0.68) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL9111192 | 0.91 | MAPKAPK2 (0.81) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL22932539 | 0.91 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL25607920 | 0.88 | MAPKAPK5 (0.56) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL15312051 | 0.87 | MAPKAPK5 (0.71) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL9109378 | 0.87 | MAPKAPK5 (0.71) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL9110803 | 0.86 | MAPKAPK5 (0.70) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL15311304 | 0.86 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-9359300-B2 | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359300-B2 | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359300-B2 | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274272-A1 | METHYL/DIFLUOROPHENYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, METHYL-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS, AND METHYL-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAP3K1, MAPK1, PDXK | MAPKAPK5 44/4885MAPKAPK2 28/4885MAPK14 46/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | MAPKAPK5 103/4885MAPKAPK2 6/4885MAPK14 339/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 69/4885MAPKAPK2 3/4885MAPK14 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.